Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) — Capital Reinvestment Ratio
Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) has a Capital Reinvestment Ratio of 0.84x as of December 2025, meaning it reinvests 1% of its operating cash flow (TL140.82 Million) in capital expenditures (TL117.91 Million). See MEDTR net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Meditera Tibbi Malzeme Sanayi ve Ticaret AS Capital Reinvestment Ratio (2020–2025)
This chart tracks Meditera Tibbi Malzeme Sanayi ve Ticaret AS's Capital Reinvestment Ratio across 6 annual periods. Check MEDTR capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Meditera Tibbi Malzeme Sanayi ve Ticaret AS (2020–2025)
Year-by-year Capital Reinvestment Ratio for Meditera Tibbi Malzeme Sanayi ve Ticaret AS from 2020 to 2025. For live market cap and broader valuation context, see Meditera Tibbi Malzeme Sanayi ve Ticaret stock valuation.
| Year | Reinvestment Ratio | Operating CF (TRY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.44x | TL435.35 Million | TL191.67 Million | ▲ +30.4% |
| 2024 | 0.34x | TL780.69 Million | TL263.52 Million | ▼ -9.8% |
| 2023 | 0.37x | TL801.02 Million | TL299.70 Million | ▼ -96.3% |
| 2022 | 10.07x | TL5.10 Million | TL51.35 Million | ▲ +4036.4% |
| 2021 | 0.24x | TL36.64 Million | TL8.92 Million | ▼ -14.5% |
| 2020 | 0.28x | TL73.26 Million | TL20.85 Million | — |